Giorgia Maria Marmo

Mrs. Giorgia Maria Marmo

General Surgery and Surgical-Medical Specialties, University of Catania, Catania, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GMGiorgia Maria Marmo
Giorgia Maria Marmo
MMMorena Munzone
Morena Munzone
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
Roberto CampagnaRoberto Campagna
Roberto Campagna
MMMarco Mascitti
Marco Mascitti
Gaetano IsolaGaetano Isola
Gaetano Isola
Oral squamous cell carcinoma (OSCC) remains one of the most prevalent and aggressive malignancies worldwide, with late diagnosis contributing to poor survival rates. Recent evidence suggests that periodontitis may act as a co-factor in development of OSCC through persistent inflammation, microbial dysbiosis, and subsequent tissue remodeling. Identifying molecular signatures that link periodontitis with early oral cancerization is therefore of paramount importance for risk assessment, prevention, and timely intervention. This narrative review aims to provide an integrative overview of the current knowledge on molecular, genetic, and epigenetic biomarkers associated with oral cancer risk in patients with periodontitis. Specifically, periodontal pathogens such as Porphyromonas gingivalis and Fusobacterium nucleatum promote oral cancerization by modulating molecular, genetic, and epigenetic pathways, including p53, Cyclin D1, Ki-67, p16INK4A, DNA methylation, histone modifications, and microRNA regulation. Therefore, this review provides a discussion about the role of inflammatory mediators, oxidative stress-related molecules, microbial-derived products, genetic markers and epigenetic mechanisms as early molecular signals of malignant transformation. The study of these salivary biomarkers (salivaomics) has emerged as a promising non-invasive diagnostic tool, although variability in sampling, biomarker stability, and confounding factors such as coexisting periodontal disease remain significant limitations. By synthesizing the available evidence, this review summarizes recent evidence linking periodontitis to oral cancerization, highlights potential salivary, proteomic, and inflammatory biomarkers, and considers the role of periodontal therapy in improving inflammatory profiles and modulating tumor-related biomarkers. Finally, it explores future perspectives, including the integration of Artificial Intelligence (AI) to enhance biomarker-based diagnosis and risk stratification in OSCC patients.

11 August 2025 in Oncologie
Verified
Journal Article
Open access
PDF file
MMMorena Munzone
Morena Munzone
GMGiorgia Maria Marmo
Giorgia Maria Marmo
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
Anand MaryaAnand Marya
Anand Marya
Andrea BlasiAndrea Blasi
Andrea Blasi
Gaetano IsolaGaetano Isola
Gaetano Isola
Periodontal inflammation, a hallmark of periodontitis, has well-known detrimental effects on oral health. Emerging evidence suggests it may also contribute to the development of oral squamous cell carcinoma (OSCC) as well as the progression of oral potentially malignant disorders (OPMDs). Chronic periodontal inflammation may contribute to oncogenesis through multiple mechanisms. The underlying biology involves the inflammatory cytokines production, immune cell infiltration, oxidative stress, and their impact on cellular behavior. Furthermore, low-grade systemic inflammation emerging from microbial dysbiosis may promote cancer cell survival, proliferation, and immune evasion – key processes in carcinogenesis. The interaction between periodontal pathogens and host tissues is closely intertwined with the progression toward epithelial dysplasia, epithelial–mesenchymal transition (EMT), and neoangiogenesis. While most of the evidence supports the association between OSCC and periodontitis, the limitations of these studies, the presence of confounding factors, and conflicting findings call this relationship into question. In this context, this review aims to discuss the most recent evidence regarding the link between periodontitis and oral carcinogenesis, with a particular focus on the ecological and molecular mechanisms underlying epithelial dysplasia, tumor initiation, progression and metastasis, while also providing new perspectives for its prevention and treatment.

15 July 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
FGFederica Di Gregorio
Federica Di Gregorio
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
GMGiorgia Maria Marmo
Giorgia Maria Marmo
AAAngela Angjelova
Angela Angjelova
EJElena Jovanova
Elena Jovanova
Gaetano IsolaGaetano Isola
Gaetano Isola
Background: Recent scientific evidence indicates that the oral–gut axis represents a critical interface in host–microbiota interactions, carrying profound implications for both periodontal and gastrointestinal diseases. This scoping review aims to evaluate the reciprocal influence between periodontitis and inflammatory bowel disease (IBD). Specifically, the underlying mechanisms of microbial translocation, immune interaction, and metabolite-mediated signaling linking the oral microbiota to gut microbial ecology are critically evaluated. Methods: Studies were selected from the PubMed, Web of Science, and Scopus databases up to May 2026. Eligible criteria included in vivo studies written in English and conducted within the last 10 years, whereas human studies involving participants under 18 years of age were excluded. The included studies analyze the effects of oral and gut dysbiosis on the opposing district. Through the database search, 2094 records were identified, and 34 articles were selected based on the eligibility criteria. Results: The included studies demonstrate the interconnection between the oral and gut microbiota. The included studies reveal that predominant oral taxa, specifically Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans, alter intestinal microbial composition. In particular, P. gingivalis colonizes the gut, exacerbating both oral and intestinal inflammation by stimulating pro-inflammatory cytokine expression via Th17 cell activation. Finally, salivary microbial composition appears to be associated with the presence and status of IBD. Conclusions: Understanding these interconnected microbial ecosystems provides valuable insights that may support the future development of integrated diagnostic and therapeutic strategies for patients suffering from periodontitis and IBD. Further large-scale studies with longer follow-up periods are required to standardize potential salivary markers and multidisciplinary therapeutic protocols for the management of periodontitis and IBD.

16 July 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
MMMorena Munzone
Morena Munzone
GMGiorgia Maria Marmo
Giorgia Maria Marmo
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
EJElena Jovanova
Elena Jovanova
AAAngela Angjelova
Angela Angjelova
Gaetano IsolaGaetano Isola
Gaetano Isola
Periodontitis is a chronic inflammatory disease increasingly recognized as a manifestation of complex microbial dysbiosis extending beyond the oral cavity. Recent advances in spatial metagenomics provide unprecedented resolution to investigate microbial community structure, function, and localization within periodontal niches and along the oral–gut axis. This review aims to explore how spatially resolved metagenomic approaches refine our understanding of the ecological and functional shifts in bacterial populations associated with periodontitis and their systemic implications. By integrating spatial mapping with shotgun metagenomics, we highlight distinct microenvironmental signatures within periodontal pockets, characterized by anaerobic pathobionts, metabolic reprogramming, and localized inflammatory gradients. Furthermore, we examine evidence supporting bidirectional interactions between oral and gut microbiota, suggesting that oral-derived taxa may contribute to gut dysbiosis through translocation and ecological disruption. From a basic science perspective, spatial metagenomics reveals niche-specific microbial functions and interspecies interactions that are not captured by bulk sequencing. Clinically, these insights open avenues for precision diagnostics and targeted therapeutics, including microbiome modulation strategies tailored to spatial microbial organization. Overall, this work underscores the importance of spatial context in metagenomic analyses and advances the conceptual framework linking periodontal disease to systemic microbial dysbiosis.

Verified
Journal Article
Open access
PDF file
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
Roberto CampagnaRoberto Campagna
Roberto Campagna
Giovanni TossettaGiovanni Tossetta
Giovanni Tossetta
Paolo PescePaolo Pesce
Paolo Pesce
GMGiorgia Maria Marmo
Giorgia Maria Marmo
Gaetano IsolaGaetano Isola
Gaetano Isola
Oral lichen planus (OLP) is a chronic, immune-mediated condition in which the oral epithelium acts simultaneously as a target of cytotoxic injury and a driver of persistent mucosal inflammation. This narrative review examines Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling as a network of cell- and cytokine-dependent signaling modules rather than a single linear pathway. Human OLP tissues show elevated expression of JAK1, phosphorylated JAK1, and various STAT-family proteins across both epithelial and inflammatory compartments. Functional modules demonstrate that IFN-γ–JAK1/JAK2–STAT1 sensitizes basal keratinocytes to cytotoxic attack, while JAK2/STAT3 regulates epithelial survival, tight-junction integrity, and E-cadherin/CD103-dependent intraepithelial lymphocyte retention. Additionally, metabolic and redox inputs converge on the STAT3–CCL5 axis to reinforce T-cell recruitment, with spatial analyses placing cytotoxic T cells directly at the epithelial interface. Although clinical responses to targeted JAK inhibitors (including JAK1, JAK1/2, JAK1/3, JAK3/TEC, and TYK2 agents) are encouraging, most current evidence remains observational. Because inhibitor selectivity is relative, therapeutic efficacy alone cannot identify the primary upstream cytokine driver. Advancing OLP management requires moving beyond broad pathway inhibition toward spatially resolved phospho-endotyping linked with standardized clinical phenotypes, mechanistic biomarkers, and targeted local therapies to enable a true precision treatment strategy.